Cite
Boye KS, Botros FT, Haupt A, et al. Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population. Diabetes Ther. 2018;9(2):637-650doi: 10.1007/s13300-018-0377-5.
Boye, K. S., Botros, F. T., Haupt, A., Woodward, B., & Lage, M. J. (2018). Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population. Diabetes therapy : research, treatment and education of diabetes and related disorders, 9(2), 637-650. https://doi.org/10.1007/s13300-018-0377-5
Boye, Kristina S, et al. "Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population." Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 9,2 (2018): 637-650. doi: https://doi.org/10.1007/s13300-018-0377-5
Boye KS, Botros FT, Haupt A, Woodward B, Lage MJ. Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population. Diabetes Ther. 2018 Apr;9(2):637-650. doi: 10.1007/s13300-018-0377-5. Epub 2018 Feb 19. PMID: 29460259; PMCID: PMC6104268.
Copy
Download .nbib